文献速递免疫规划

既往MIS-C儿童接种SARS-CoV-2疫苗后的体液、T细胞及免疫基因表达反应

Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.
PubMed 文献 · Vaccine · 2025-07-06

研究纳入3例既往多系统炎症综合征(MIS-C)儿童和4例健康儿童,均接种两剂BNT162b2疫苗。接种后两组的Spike结合抗体和中和抗体活性均升高且组间无差异,血清炎性细胞因子和全血免疫基因谱未呈现急性MIS-C样改变,所有受试者在第二剂后3周均产生强效SARS-CoV-2特异性T细胞反应。

要点

  • 既往MIS-C儿童接种BNT162b2后Spike结合抗体和中和抗体活性升高,与健康儿童无差异。
  • 接种后血清炎性细胞因子和全血免疫基因谱未呈现急性MIS-C样改变,两组各时间点无差异。
  • 所有受试者在第二剂后3周均产生强效SARS-CoV-2特异性T细胞反应。

核心结论

  • vaccination is effective at boosting SARS-CoV-2-specific immune responses in a small group of children with previous MIS-C, and that it does not induce inflammatory cytokine or gene expression responses resembling acute MIS-C.
  • Although larger-scale studies are needed to confirm these findings, the present evidence supports SARS-CoV-2 vaccination in children with previous MIS-C.

研究设计与样本

  • 研究纳入3例既往MIS-C儿童和4例健康儿童,均接种两剂BNT162b2疫苗。
  • 于第一剂前、第一剂后1周、第二剂后1周及第二剂后3周采集血液。

主要发现

  • 所有受试者接种前均可检测到SARS-CoV-2刺突IgG。
  • 第一剂后刺突结合抗体和中和抗体活性升高,既往MIS-C儿童与健康儿童之间无差异。
  • 血清炎性细胞因子和全血免疫基因谱未呈现急性MIS-C样改变,两组各时间点无差异。
  • 所有受试者在第二剂后3周均产生强效SARS-CoV-2特异性T细胞反应。
  • 2例既往MIS-C儿童出现表达TCR Vβ21.3的SARS-CoV-2特异性CD4 T细胞短暂增加,健康儿童中无此现象。

临床怎么用

  • 作者认为,尽管需要更大规模研究确认,现有证据支持既往MIS-C儿童接种SARS-CoV-2疫苗。

局限性

  • Although larger-scale studies are needed to confirm these findings.

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effects of SARS-CoV-2 vaccination in children with previous multisystem inflammatory syndrome (MIS-C) are not well understood. In this study, we aimed to assess immune responses to SARS-CoV-2 vaccination in children over the age of 12 years with previous MIS-C and compare them to healthy children. Three children with previous MIS-C and four healthy children received two doses of the BNT162b2 vaccine. Blood was collected before the first dose, one week after the first dose, one week after the second dose and three weeks after the second dose. All participants had detectable SARS-CoV-2 spike IgG before vaccination. Spike binding and neutralising antibody activity increased after the first vaccine dose with no differences between children with a history of MIS-C and healthy children. Serum inflammatory cytokines and whole blood immune gene profiles did not resemble acute MIS-C and there were no differences in these between the two groups at any timepoint. All participants gained a robust SARS-CoV-2-specific T cell response by three weeks after the second dose. A transient increase in SARS-CoV-2-specific CD4 T cells expressing TCR Vβ21.3, a non-specific T cell subset previously found to be enriched in patients with MIS-C, was demonstrated in two of the children with previous MIS-C but none of the healthy children. Together, these data demonstrate that vaccination is effective at boosting SARS-CoV-2-specific immune responses in a small group of children with previous MIS-C, and that it does not induce inflammatory cytokine or gene expression responses resembling acute MIS-C. Although larger-scale studies are needed to confirm these findings, the present evidence supports SARS-CoV-2 vaccination in children with previous MIS-C.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Spracklen TF, Day J, Van Der Ross H, et al. Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C. Vaccine. 2025. PMID: 40618623. doi:10.1016/j.vaccine.2025.127461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。